

ASX ANNOUNCEMENT

27 May 2026

Multi-centre BMB18 clinical trial commences across Australia and Greece

Highlights

- Multi-centre randomised clinical trial of BMB18 (*Lactiplantibacillus plantarum*, DSM 35214) commencing this week across two international academic sites: La Trobe University in Melbourne and Harokopio University of Athens (HUA)
- Three-arm, double-blind, placebo-controlled protocol evaluating two BMB18 dosage levels (1×10^9 CFU/day and 10×10^9 CFU/day) against placebo across 240 participants over a six-week intervention with two-week follow-up
- HUA ranked 2nd in Greece, and 1st in Greece for Research Quality, in the Times Higher Education World University Rankings 2026
- Athens site led by Professor George Moschonis, Professor of Human Nutrition at HUA
- BMB18 is Biome's first wholly proprietary strain
- Recruitment commencing this week within the Q4 FY26 timeline disclosed on 27 April 2026
- All site agreements executed; ethics approvals in place at both centres; clinical trial product manufactured, released and delivered

Biome Australia Limited (ASX: BIO) (Biome or the Company) is pleased to provide a material update to the announcement released on 27 April 2026 (Patent Application Filed for Probiotic Strain BMB18).

Multi-centre design across two academic centres

The BMB18 clinical trial has been expanded from a single-centre study at La Trobe University to a multi-centre international program, with **Harokopio University of Athens (HUA)** activated as a concurrent second site under the leadership of **Professor George Moschonis**, Professor of Human Nutrition at HUA. This is the first time the second-site addition has been disclosed to the market.

Harokopio University of Athens is ranked 2nd in Greece in the Times Higher Education (THE) World University Rankings 2026, and 1st in Greece in the Research Quality pillar of that ranking. The University's School of Health Science and Education, which houses the Department of Nutrition and Dietetics, is widely recognised across Europe for its clinical nutrition and dietetics research output.

The 240-participant protocol is a randomised, double-blind, placebo-controlled, three-arm study evaluating two BMB18 dosage levels (1×10^9 CFU/day and 10×10^9 CFU/day) against a matched placebo over a six-week intervention period, with a two-week post-intervention follow-up. Both centres operate to a harmonised protocol, with site agreements executed in materially equivalent terms. The dose-response design is intended to generate the first human clinical evidence for the strain across two independent academic populations.

Recruitment commencing within previously disclosed timeline

Recruitment is commencing this week at both sites, consistent with the Q4 FY26 trial commencement timeline disclosed in the Company's announcement of 27 April 2026. All site agreements have been executed, ethics clearances are in place at both centres, and clinical trial product has been manufactured, released and delivered to both sites.

About BMB18

BMB18 (*Lactiplantibacillus plantarum*, DSM 35214) is the first wholly proprietary strain in Biome's intellectual property pipeline. Pre-clinical work has characterised a triple mechanism of action across intestinal barrier function, immunomodulation and antioxidant activity. A patent application covering the strain and its applications has been filed and is pending examination, with the corresponding Budapest Treaty patent deposit at DSMZ in progress.

Clinical trial results cannot be predicted and patent applications are subject to examination. Biome will provide further updates on the program in accordance with its continuous disclosure obligations.

Blair Vega Norfolk, Founder and Managing Director of Biome Australia, said:

"Expanding the BMB18 program to a multi-centre international design, with two internationally respected academic centres running concurrently under Professor Moschonis in Athens and the existing team at La Trobe in Melbourne, materially strengthens the credibility and recruitment footprint of the trial. Commencing recruitment this week at both sites, within the timeline previously disclosed, is an important step in the maturation of Biome's proprietary IP platform."



Source: Times Higher Education World University Rankings 2026,
www.timeshighereducation.com/world-university-rankings/harokopio-university-athens.

–ENDS–

Approved for release by the Biome Australia board of directors.

Investor Hub

Biome has launched a new interactive investor hub. To view a video presentation of this announcement, ask questions or sign up for future company updates, please visit the investor hub at <https://investorhub.biomeaustralia.com/>.

About Biome Australia Limited

Biome Australia develops, licences, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. *Biome* aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, *Biome* distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, *Biome* produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: *Activated Probiotics*®.

Supported by clinical research, including randomised double-blind placebo-controlled trials, *Activated Probiotics* and *Activated Therapeutics* help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, *Biome* is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations

Lauren Dwyer



corporate@biomeaustralia.com
(03) 9017 5800

Forward Looking Statements

This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (Forward Looking Statements). Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Patent applications are subject to examination processes and grant is not guaranteed. Clinical trial results cannot be predicted and may not support commercial development. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.



For personal use only

